A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632
Rintaro Noro, Satoshi Igawa, Akihiro Bessho, Takashi Hirose, Tsuneo Shimokawa, Masanao Nakashima, Koichi Minato, Nobuhiko Seki, Takaaki Tokito, Toshiyuki Harada, Shinji Sasada, Shingo Miyamoto, Yosuke Tanaka, Naoki Furuya, Takayuki Kaburagi, Hideki Hayashi, Hirotoshi Iihara, Hiroaki Okamoto, Kaoru Kubota
Topics & Concepts
AfatinibMedicineInternal medicineClinical endpointLung cancerAdverse effectOncologyPhases of clinical researchEpidermal growth factor receptorConfidence intervalSurgeryCancerClinical trialGastroenterologyGefitinibLung Cancer Treatments and MutationsFibroblast Growth Factor ResearchLung Cancer Research Studies